ArticleBMC infectious diseases2019
Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies.European journal of pharmacology · 2021Pooled it
- The effect of age on the incidence of COVID-19 complications: a systematic review and meta-analysis.Systematic reviews · 2021Pooled it
- Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review ofTheranostics · 2021Pooled it
- Pooled it
- Potential treatments of COVID-19: Drug repurposing and therapeutic interventions.Journal of pharmacological sciences · 2023Review
- Article
- COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Review
- Controversies' clarification regarding ribavirin efficacy in measles and coronaviruses: Comprehensive therapeutic approach strictly tailored to COVID-19 disease stages.World journal of clinical cases · 2021Article
- New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.Journal of medical virology · 2021Article
- Epidemiology of 631 Cases of COVID-19 Identified in Jiangsu Province Between January 1st and March 20th 2020: Factors Associated with Disease Severity and Analysis of Zero Mortality.Medical science monitor : international medical journal of experimental and clinical research · 2021Article
- SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021Review
- Middle East respiratory syndrome coronavirus infection profile in Qatar: An 8-year experience.IDCases · 2021Article
- Development of septic shock and prognostic assessment in critically ill patients with coronavirus disease outside Wuhan, China.World journal of emergency medicine · 2021Article
- Impact of Fundamental Diseases on Patients With COVID-19.Disaster medicine and public health preparedness · 2020Article
- Demographic, clinical, and outcomes of confirmed cases of Middle East Respiratory Syndrome coronavirus (MERS-CoV) in Najran, Kingdom of Saudi Arabia (KSA); A retrospective record based study.Journal of infection and public health · 2020Article
- Emerging Therapeutic Modalities against COVID-19.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Covid-19 Pandemic and Current Medical Interventions.Archives of medical research · 2020Review
- Effect of coronavirus infection on the human heart: A scoping review.European journal of preventive cardiology · 2020Article
- Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19.Journal of medical virology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMortality is high among patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. We aimed to determine hospital mortality and the factors associated with it in a cohort of MERS-CoV patients.
methodsWe reviewed hospital records of confirmed cases (detection of virus by polymerase chain reaction from respiratory tract samples) of MERS-CoV patients (n = 63) admitted to Buraidah Central Hospital in Al-Qassim, Saudi Arabia between 2014 and 2017. We abstracted data on demography, vital signs, associated conditions presented on admission, pre-existing chronic diseases, treatment, and vital status. Bi-variate comparisons and multiple logistic regressions were the choice of data analyses.
resultsThe mean age was 60 years (SD = 18.2); most patients were male (74.6%) and Saudi citizens (81%). All but two patients were treated with Ribavirin plus Interferon. Hospital mortality was 25.4%. Patients who were admitted with septic shock and/or organ failure were significantly more likely to die than patients who were admitted with pneumonia and/or acute respiratory distress syndrome (OR = 47.9, 95% CI = 3.9, 585.5, p-value 0.002). Age, sex, and presence of chronic conditions were not significantly associated with mortality.
conclusionHospital mortality was 25%; septic shock/organ failure at admittance was a significant predictor of mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.